Volkswagen Korea launched the all-new Jetta compact sedan in the local market geared toward expanding its product lineup by 2021.
The carmaker intends to boost sales and regain consumer confidence in South Korea after its emission scandal last year.
With the Jetta, the company hopes to lure South Korean customers who want imported but affordable cars.
According to Volkswagen Korea Executive Director Stefan Krapp, they plan to add the Passat GT sedan in December, the T-ROC compact SUV in February 2021, and the Golf in late 2021.
Krapp revealed that by 2021, Volkswagen would again feature a full lineup in the Korean market.
Volkswagen Korea intends to make imported cars available for all Korean customers, thereby not positioning them as premium, non-reachable products.
Volkswagen Korea's existing models consist of the Arteon sedan, Tiguan, Tiguan Allspace, and Touareg SUV.


Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery
One Percent Rule Checklist For Safer Forex Trading Risk
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10%
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 



